PAX2 and neoplasm: Although it has been suggested that abnormal promoter methylation underlies PAX2 protein loss (19), this hypothesis lacks supporting evidence (20), and there have not been investigations establishing PAX2 as a functionally significant in vivo tumor suppressor.